Several other analysts have also recently commented on CRIS. Zacks Investment Research upgraded Curis from a sell rating to a hold rating in a report on Friday, July 8th. FBR & Co restated a buy rating on shares of Curis in a report on Thursday, September 8th. Finally, Robert W. Baird restated an outperform rating and set a $7.00 target price on shares of Curis in a report on Wednesday, September 7th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $5.05.
Shares of Curis (NASDAQ:CRIS) opened at 2.76 on Wednesday. The firm’s 50-day moving average price is $2.35 and its 200 day moving average price is $1.90. The firm’s market cap is $357.34 million. Curis has a 12-month low of $1.25 and a 12-month high of $3.42.
Curis (NASDAQ:CRIS) last announced its earnings results on Thursday, August 4th. The company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09). The company had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $2.05 million. Curis had a negative return on equity of 65.51% and a negative net margin of 526.72%. The business’s revenue for the quarter was down 19.0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.06) earnings per share. On average, equities analysts expect that Curis will post ($0.37) earnings per share for the current fiscal year.
In other news, major shareholder Discovery Technologie Aurigene purchased 10,208,333 shares of the firm’s stock in a transaction that occurred on Wednesday, September 7th. The shares were acquired at an average price of $2.40 per share, for a total transaction of $24,499,999.20. Following the completion of the acquisition, the insider now directly owns 27,328,464 shares in the company, valued at $65,588,313.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 6.09% of the stock is owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of CRIS. TFS Capital LLC boosted its position in Curis by 92.4% in the second quarter. TFS Capital LLC now owns 425,243 shares of the company’s stock valued at $663,000 after buying an additional 204,278 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new position in Curis during the second quarter valued at $312,000. Janney Montgomery Scott LLC bought a new position in Curis during the second quarter valued at $310,000. Jacobs Levy Equity Management Inc. bought a new position in Curis during the first quarter valued at $248,000. Finally, State Street Corp raised its position in Curis by 8.7% in the second quarter. State Street Corp now owns 1,579,103 shares of the company’s stock valued at $2,464,000 after buying an additional 126,694 shares during the last quarter. Institutional investors and hedge funds own 52.36% of the company’s stock.
Curis Company Profile
Curis, Inc is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes.
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.